Mimetic Medicines
Summary
Mimetic Medicines is developing a pipeline of novel, long-acting, non-opioid drug candidates for chronic pain. Mimetic’s drug candidates take advantage of the company’s proprietary short lipidated peptidomimetic (“SLiP”) platform to target ion channel / scaffold protein complexes that become dysregulated in patients with chronic pain. The company’s lead asset, MM-1001, dubbed the “Ozempic for pain,” is a SLiP that disrupts the NR1C2/Magi2 complex and degrades a targeted subpopulation of NMDA receptors.
Team
John Strumbos, PhD Co-Founder & CEO
John Strumbos is the Chief Executive Officer at Mimetic Medicines. He brings over two decades of experience across life sciences investment, corporate finance, and biotech leadership. Prior to founding Mimetic, he held executive roles at Scipher Medicine and Immunovant (Nasdaq: IMVT), where he raised a combined $670 million in growth capital and led the successful scaling of both companies. Earlier in his career, Dr. Strumbos spent 15 years as a life sciences investor and corporate finance advisor, including roles at Goldman Sachs and Morgan Stanley. He holds a Ph.D. in Neuroscience and an MBA from Yale, and a B.A. in Neuroscience from Columbia University.
Arin Bhattacharjee, PhD Co-Founder & Scientific Advisor
Dr. Bhattacharjee is an expert in pain research and neuronal ion channel trafficking. He is a tenured professor at the U. at Buffalo’s Jacobs School of Medicine & Biomedical Sciences. He has co-authored 38 peer-reviewed journal publications and is an inventor on 3 patents, all covering therapeutic interventions for pain. Dr. Bhattacharjee completed a post-doctoral fellowship at Yale University, earned a Ph.D.in Pharmacology from the University of South Alabama, and received a B.S. in Biology from the University of Alberta.
